GSK to start Ebola vaccine trials in west Africa next month November 13, 2014 GSK says its Ebola vaccine will begin trials in west Africa next month. Safety clinical trials will take place in Mali at a treatment centre run by the charity Medicins Sans Frontieres (MSF), which has been at the forefront of tackling the virus since the epidemic started in December last year. It is hoped [...]
Is there a cure for Ebola? Inhaled vaccine could provide answer to injection worries of GSK, NewLink and Johnson & Johnson November 4, 2014 Could a newly-developed inhaled vaccine soon be used to stop the spread of Ebola between humans in west Africa? Developed by a team of researchers at a university in Texas, it has already been shown to provide long-term protection for non-human primates against the deadly virus. The formulation took seven years to create, and [...]
GlaxoSmithKline considers £17bn HIV wonder drugs split with Viiv Healthcare IPO October 22, 2014 Pharma giant GlaxoSmithKline (GSK) is considering floating its HIV drugs business in a move that would see Viiv Healthcare among the top 40 companies in the FTSE 100 with a market valuation of up to £17bn. Chief executive Andrew Witty told reporters yesterday: “In line with our commitment to identifying ways to realise shareholder value, [...]
FTSE rises after Glaxo sets out recovery plan – London Report October 22, 2014 BRITAIN’S top share index yesterday ended higher, with motor insurers advancing on news of an increase in car premiums and drugmaker GlaxoSmithKline rising after its results. The FTSE 100 finished 0.4 per cent higher at 6,399.73 points. It had fallen more than 10 per cent in four weeks before making a marginal recovery since late [...]
GSK healthcare spin-off ViiV could generate one of the biggest IPOs in history: Here are some of the most successful corporate spin-offs stories October 22, 2014 ViiV Healthcare could generate one of the biggest IPOs in history, if GSK decides to go ahead and make it a spin-off company. The pharmaceutical firm was created in 2009 as a joint venture between GSK and US firm Pfizer. It specialises in developing therapies for HIV and operates in 16 countries. With [...]
GSK share price up despite Ebola vaccine delay: Head of research says it will be “too late” for this epidemic October 17, 2014 GlaxoSmithKline (GSK) has revealed that its Ebola vaccine won't be ready in time to deal with the current epidemic in west Africa. The British pharmaceutical giant started developing the vaccine earlier this year, in conjunction with the US National Institutes of Health. It uses a single protein from the Ebola virus to set off [...]
GSK confirms RBS’ Sir Philip Hampton as new chairman September 25, 2014 GlaxoSmithKline (GSK) has confirmed that Royal Bank of Scotland (RBS) chairman Sir Philip Hampton has been appointed to lead its board. The pharmaceutical giant said this morning that Hampton will join as non-executive director on 1 January next year, assuming the role of chairman from Sir Christopher Gent from 1 September. Although RBS did not [...]
GlaxoSmithKline to name Sir Philip Hampton chair September 24, 2014 SHARES in pharmaceutical giant GlaxoSmithKline (GSK) rose slightly in late afternoon trading yesterday after it emerged that Sir Philip Hampton was likely to be named as its new chairman. GSK is likely to announce Hampton’s move in the next two days – and with such a large job he is expected to eventually give up [...]
Share price up after rumours RBS’ Sir Philip Hampton “will be named GSK chairman before the weekend” September 24, 2014 Shares in pharmaceutical giant GlaxoSmithKline rose slightly in late afternoon trading after it emerged Sir Philip Hampton is likely to be named as its new chairman. Shares climbed 0.2 per cent to 1,425p, having spent the afternoon around the 1,418p mark. GSK is likely to announce Hampton's move in the next two days – such [...]
GSK share price shows immunity to Ebola vaccine September 17, 2014 The news GSK’s Ebola vaccine is to be trialled on humans failed to lift the company on the stock market this morning, with its share price falling 0.21 per cent to 1,438 pence. The experimental vaccine is to be tested on 60 healthy adults in Oxford, after it conferred resistance on a group of [...]